Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis
- 1Qionglai Hospital of Traditional Chinese Medicine, Qionglai City, Sichuan Province 611530 China
- 2Southwest Medical University, Luzhou City, Sichuan Province 646099 China
Abstract
Background: Regorafenib is an approved later-line therapy for metastatic colorectal cancer (mCRC). Combining regorafenib with PD-1/PD-L1 blockade may enhance antitumor immunity by modifying the tumor microenvironment. This meta-analysis compared the combination with regorafenib monotherapy and explored preliminary treatment signals in microsatellite-stable/proficient mismatch repair (MSS/pMMR) mCRC.
Methods: A comprehensive search was performed in PubMed, Cochrane Library, Embase, Web of Science, and Chinese databases (Wanfang, VIP, CNKI, CBM) up to February 20, 2026. RCTs and RCSs comparing combination therapy with monotherapy were included. Outcomes were ORR, DCR, PFS, and OS, etc. Study quality was assessed using the Cochrane risk-of-bias tool for randomized trials and the Newcastle–Ottawa Scale (NOS) for observational studies. Analyses were performed using RevMan 5.4, with RR/HR and 95% CIs. Heterogeneity was assessed using I², publication bias via funnel plots, and Egger’s/Begg’s tests when applicable. Evidence certainty was graded using GRADE.
Results: Eight studies (two RCTs and six RCSs; 992 patients) were included. Compared with regorafenib monotherapy, combination therapy improved ORR (RR = 1.81, 95% CI: 1.15–2.85), DCR (RR = 1.34, 95% CI: 1.10–1.62), and PR (RR = 1.66, 95% CI: 1.07–2.59), and reduced the proportion of patients with PD at tumor assessment (RR = 0.65, 95% CI: 0.50–0.86). Combination therapy was also associated with longer PFS (HR = 0.57, 95% CI: 0.37–0.87), whereas the OS estimate was borderline and did not establish a robust survival benefit (HR = 0.73, 95% CI: 0.54–1.00; P = 0.05). Post hoc exploratory analyses based on extractable MSS/pMMR data suggested possible improvements in disease control. Combination therapy was associated with increased odds of hypertension, hypothyroidism, hand-foot skin reaction, liver function abnormalities, and nausea; however, comparative evidence for grade ≥ 3 toxicity was insufficient because reporting was inconsistent.
Conclusion: Regorafenib plus PD-1/PD-L1 inhibitors may improve tumor response and PFS compared with regorafenib monotherapy in refractory mCRC, but a definitive OS advantage has not been established. The MSS/pMMR findings remain exploratory and hypothesis-generating. Adequately powered, biomarker-stratified randomized trials with standardized MSI/MMR assessment, consistent safety reporting, and longer follow-up are required before this combination can be considered a standard later-line treatment.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12957-026-04536-8.
Related
- Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis
- Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial
- Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis
- Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy ± bevacizumab for recurrent or metastatic cervical cancer: a systematic review and meta-analysis of randomized controlled trials
- Efficacy and safety of a cetuximab biosimilar compared with Erbitux in patients with RAS wild-type metastatic colorectal cancer
BibTeX
@article{zhong2026efficacy,
title = {{Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis}},
author = {Yan Zhong and Xianhang Li and Siqi Chen and Min Deng},
journal = {World Journal of Surgical Oncology},
year = {2026},
month = aug,
doi = {10.1186/s12957-026-04536-8},
url = {https://doi.org/10.1186/s12957-026-04536-8},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Efficacy and safety of regorafenib plus PD-1/PD-L1 inhibitors for metastatic colorectal cancer: a systematic review and meta-analysis
AU - Yan Zhong
AU - Xianhang Li
AU - Siqi Chen
AU - Min Deng
PY - 2026
DA - 2026/08/10
JO - World Journal of Surgical Oncology
DO - 10.1186/s12957-026-04536-8
UR - https://doi.org/10.1186/s12957-026-04536-8
AB - Background: Regorafenib is an approved later-line therapy for metastatic colorectal cancer (mCRC). Combining regorafenib with PD-1/PD-L1 blockade may enhance antitumor immunity by modifying the tumor microenvironment. This meta-analysis compared the combination with regorafenib monotherapy and explored preliminary treatment signals in microsatellite-stable/proficient mismatch repair (MSS/pMMR) mCRC. Methods: A comprehensive search was performed in PubMed, Cochrane Library, Embase, Web of Science, and Chinese databases (Wanfang, VIP, CNKI, CBM) up to February 20, 2026. RCTs and RCSs comparing combination therapy with monotherapy were included. Outcomes were ORR, DCR, PFS, and OS, etc. Study quality was assessed using the Cochrane risk-of-bias tool for randomized trials and the Newcastle–Ottawa Scale (NOS) for observational studies. Analyses were performed using RevMan 5.4, with RR/HR and 95% CIs. Heterogeneity was assessed using I², publication bias via funnel plots, and Egger’s/Begg’s tests when applicable. Evidence certainty was graded using GRADE. Results: Eight studies (two RCTs and six RCSs; 992 patients) were included. Compared with regorafenib monotherapy, combination therapy improved ORR (RR = 1.81, 95% CI: 1.15–2.85), DCR (RR = 1.34, 95% CI: 1.10–1.62), and PR (RR = 1.66, 95% CI: 1.07–2.59), and reduced the proportion of patients with PD at tumor assessment (RR = 0.65, 95% CI: 0.50–0.86). Combination therapy was also associated with longer PFS (HR = 0.57, 95% CI: 0.37–0.87), whereas the OS estimate was borderline and did not establish a robust survival benefit (HR = 0.73, 95% CI: 0.54–1.00; P = 0.05). Post hoc exploratory analyses based on extractable MSS/pMMR data suggested possible improvements in disease control. Combination therapy was associated with increased odds of hypertension, hypothyroidism, hand-foot skin reaction, liver function abnormalities, and nausea; however, comparative evidence for grade ≥ 3 toxicity was insufficient because reporting was inconsistent. Conclusion: Regorafenib plus PD-1/PD-L1 inhibitors may improve tumor response and PFS compared with regorafenib monotherapy in refractory mCRC, but a definitive OS advantage has not been established. The MSS/pMMR findings remain exploratory and hypothesis-generating. Adequately powered, biomarker-stratified randomized trials with standardized MSI/MMR assessment, consistent safety reporting, and longer follow-up are required before this combination can be considered a standard later-line treatment. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12957-026-04536-8.
SN - 1477-7819
ER -